Current State of Therapeutics for HTLV-1
Open accessThe DOI matches its Crossref record; 353 of the 372 references it cites were found in a registry or an index; 84 of the 236 sources its claims cite were checked for support.
Abstract
Human T cell leukaemia virus type-1 (HTLV-1) is an oncogenic retrovirus that causes lifelong infection in ~5–10 million individuals globally. It is endemic to certain First Nations populations of Northern and Central Australia, Japan, South and Central America, Africa, and the Caribbean region. HTLV-1 preferentially infects CD4+ T cells and remains in a state of reduced transcription, often being asymptomatic in the beginning of infection, with symptoms developing later in life. HTLV-1 infection is implicated in the development of adult T cell leukaemia/lymphoma (ATL) and HTLV-1-associated myelopathies (HAM), amongst other immune-related disorders. With no preventive or curative interventions, infected individuals have limited treatment options, most of which manage symptoms. The clinical burden and lack of treatment options directs the need for alternative treatment strategies for HTLV-1 infection. Recent advances have been made in the development of RNA-based antiviral therapeutics for Human Immunodeficiency Virus Type-1 (HIV-1), an analogous retrovirus that shares modes of transmission with HTLV-1. This review highlights past and ongoing efforts in the development of HTLV-1 therapeutics and vaccines, with a focus on the potential for gene therapy as a new treatment modality in light of its successes in HIV-1, as well as animal models that may help the advancement of novel antiviral and anticancer interventions.
Overview
CoChat Summary
## TL;DR
This review argues that HTLV-1 still lacks approved curative or preventive therapy, and that current treatment is largely symptomatic or repurposed from HIV and oncology drugs. It highlights gene-targeting approaches, especially RNAi and gene editing, plus BLV vaccination as the most promising directions for future HTLV-1 interventions.
## Key findings
- HTLV-1 causes lifelong infection in an estimated ~5–10 million people globally, with global prevalence estimates ranging from 3 to 30 million cases.
- The lifetime risk of ATL in carriers is estimated at 1–5%, and the risk of HAM at about 3%; among carriers, the risk of early neurological disorders can be as high as 24%.
- Existing ART has limited impact because it cannot eliminate HTLV-1 reservoirs driven by clonal expansion; for example, AZT + lamivudine in a randomized double-blind placebo-controlled HAM trial produced no significant reduction in PVL or clinical measures after 24 weeks.
- In HAM, a multicentre randomized phase III mogamulizumab study found no significant difference in the primary or secondary motor endpoints at the end of the double-blind period, but it did significantly reduce PVL and CSF CXCL10/neopterin; earlier phase I/IIa data in 21 patients reported improved motor ability in 32% and reduced spasticity in 79%.
- The BLV vaccine is presented as a model for HTLV-1 vaccination: in Argentina it conferred immunity in 28 of 29 cows over 4 years and was reported as safe and effective.
## Methods
- Narrative review of past and ongoing HTLV-1 therapeutics and vaccines, with emphasis on similarities to HIV-1 and on gene therapy/RNA-based approaches.
- Synthesizes evidence from cell models, animal models (mice, rabbits, non-human primates, humanized mice), and clinical studies/trials in ATL and HAM.
- Main analysis is comparative and descriptive, evaluating how different therapeutic strategies affect PVL, viral gene expression, tumor burden, and clinical outcomes.
## Limitations
- The paper states that there are no preventive or curative interventions for HTLV-1 and that there are no approved HTLV-1-specific inhibitors or antiviral ASOs.
- For HAM and other HTLV-1-associated inflammatory diseases, the paper notes that studies are often observational, with small cohorts and geographic constraints.
- Evident from the text: much of the evidence comes from preclinical models, and the review itself notes major gaps in in vivo/in vitro HTLV-1 studies, efficient delivery for gene therapies, and clinical translation of RNAi/gene-editing approaches.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures






Verification
Claims the paper makes
63 Valid · 10 Not valid · 85 Not checked · 51 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“HTLV-1 is primarily associated with the aggressive haematological malignancy ATL [1,2] and a chronic inflammatory disease called HTLV-1-associated myelopathies (HAM).”
§ Current State of Therapeutics for HTLV-1 > 1. Introduction > 1.5. HTLV-1-Associated Diseases
What the sources say
- Partly supportedcites [1] Poiesz, 1980, Detection and isolation of type C retrovirus particles from fresh and cultured lymphocytes of a patient with cutaneous T-cell lymphoma, Proc. Natl. Acad. Sci. USA sourceExperimental — accuracy not yet measured
The paper reports HTLV particles in lymphocytes from a patient with cutaneous T-cell lymphoma (mycosis fungoides), supporting an association with a T-cell malignancy. It does not establish the more specific claim that HTLV-1 is primarily associated with ATL. The citation in the printed sentence is attached to ATL, not HAM. (LLM, conf=0.78)
- Partly supportedcites [2] Hinuma, 1981, Adult T-cell leukemia: Antigen in an ATL cell line and detection of antibodies to the antigen in human sera, Proc. Natl. Acad. Sci. USA sourceExperimental — accuracy not yet measured
Our copy of Hinuma et al. 1981 supports only the ATL half of the sentence: the Abstract and Results (p. 1-2) report anti-ATLA antibodies in all 44 ATL patients and in most T-cell lymphoma patients, and the Introduction describes ATL as a rapidly progressing, treatment-resistant malignancy — though the paper hedges the link ('The present results suggest, but do not prove a causal relationship between a type C virus and ATL', DISCUSSION) and never uses the name HTLV-1, calling the antigen ATLA and the particle a type C virus. The second attributed element, association with HTLV-1-associated myelopathy (HAM), is absent: searches for 'myelopathy', 'HAM' and 'tropical spastic paraparesis' returned no passage in our copy. The HAM association is therefore not supported by this source. (LLM, conf=0.75)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“An ongoing issue of HTLV-1-infected cell lines is the underrepresentation of more divergent subtypes, with recent studies suggesting that different HTLV-1 subtypes exert significantly different influences over the host immune system compared to the dominant cosmopolitan subtype [19].”
§ Current State of Therapeutics for HTLV-1 > 2. In Vivo Assessment of Therapeutics > 2.1. Cell Models
What the sources say
- Partly supportedcites [19] Afonso, 2019, Molecular epidemiology, genetic variability and evolution of HTLV-1 with special emphasis on African genotypes, Retrovirology sourceExperimental — accuracy not yet measured
In “The genetic organization differs according to molecular genotypes” (page not provided), the review says HTLV-1b and HTLV-1c lack some accessory genes present in HTLV-1a and that one HTLV-1a accessory protein facilitates immune escape. It does not establish that different subtypes exert significantly different effects on the host immune system; it presents the implications of those genetic differences as hypotheses. (LLM, conf=0.83)
hedgedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“with previous studies suggesting a distinct pathogenesis [96,118,119,120].”
§ Current State of Therapeutics for HTLV-1 > 2. In Vivo Assessment of Therapeutics > 2.1. Cell Models
What the sources say
- Not checked — no full text of the sourcecites [96] Einsiedel, 2012, Bronchiectasis is associated with human T-lymphotropic virus 1 infection in an Indigenous Australian population, Clin. Infect. Dis. source
- Could not verifycites [118] Talukder, M.R., Pham, H., Woodman, R., Wilson, K., Taylor, K., Kaldor, J., and Einsiedel, L. (2022). The Association between Diabetes and Human T-Cell Leukaemia Virus Type-1 (HTLV-1) with Strongyloides stercoralis: Results of a Community-Based, Cross-Sectional Survey in Central Australia. Int. J. Environ. Res. Public Health, 19. sourceExperimental — accuracy not yet measured
The Introduction describes immune effects of HTLV-1 infection in people with Strongyloides, and Methods §2.5 mentions HTLV-1c only to identify the sequence targeted by a test. Neither passage says HTLV-1c has a distinct pathogenesis. Searches for “pathogenesis” and subtype-specific differences found no passage addressing that claim. (LLM, conf=0.74)
- Not checked — no full text of the sourcecites [119] Talukder, 2021, Risk factors for HTLV-1, acute kidney injury, and urinary tract infection among aboriginal adults with end stage kidney disease in central Australia, J. Med. Virol. source
- Not checked — no full text of the sourcecites [120] Talukder, 2023, High Human T-Cell Leukemia Virus Type 1c Proviral Loads Are Associated With Diabetes and Chronic Kidney Disease: Results of a Cross-Sectional Community Survey in Central Australia, Clin. Infect. Dis. source
hedged- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Every source the paper cites for this claim was checked and supports it.
In the paper
“Overexpression of Hbz was observed to prevent Tax-induced NF-κB and PRC2 activation, shedding light on the co-modulatory interplay of Tax and Hbz [157].”
§ Current State of Therapeutics for HTLV-1 > 2. In Vivo Assessment of Therapeutics > 2.2. Animal Models
What the sources say
- Supportedcites [157] Akkouche, A., Moodad, S., Hleihel, R., Skayneh, H., Chambeyron, S., El Hajj, H., and Bazarbachi, A. (2021). In vivo antagonistic role of the Human T-Cell Leukemia Virus Type 1 regulatory proteins Tax and HBZ. PLoS Pathog., 17. source
The Results section reports that flies overexpressing both HBZ and Tax had significantly attenuated Tax-mediated NF-κB and PRC2 activation compared with flies expressing Tax alone; its Fig. 3 caption describes this as abrogation. A separate Results section reports that HBZ overexpression blocked Tax-induced PRC2 activation in human cells. Page numbers were not available in our copy. (LLM, conf=0.93)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The cessation of therapy in HIV is associated with a strong viral rebound to pre-therapeutic plasma viral loads [164,165,166]”
§ Current State of Therapeutics for HTLV-1 > 3. Current Treatments > 3.1. Antiretroviral Therapies and Limitations for HTLV-1
What the sources say
- Supportedcites [164] Hamlyn, E., Ewings, F.M., Porter, K., Cooper, D.A., Tambussi, G., Schechter, M., Pedersen, C., Okulicz, J.F., McClure, M., and Babiker, A. (2012). Plasma HIV viral rebound following protocol-indicated cessation of ART commenced in primary and chronic HIV infection. PLoS ONE, 7. source
The Introduction states that plasma viral load after ART cessation can reach levels comparable to pre-treatment values. The Discussion also reports that participants who began ART during primary HIV infection reached pre-ART viral-load levels after a median of 50 weeks. (LLM, conf=0.92)
- Partly supportedcites [165] Chun, 2010, Rebound of plasma viremia following cessation of antiretroviral therapy despite profoundly low levels of HIV reservoir: Implications for eradication, AIDS sourceExperimental — accuracy not yet measured
The Results report that plasma viremia rebounded after ART was stopped in one participant, reaching 1,593 and later 8,684 HIV RNA copies/ml. The Discussion says rebound is likely for the vast majority of people receiving ART. Neither passage establishes that viral loads returned to pre-therapy levels; the reported rebound was also delayed by 50 days in the participant studied. (LLM, conf=0.86)
- Not checked — no full text of the sourcecites [166] Colven, 2000, Retroviral rebound syndrome after cessation of suppressive antiretroviral therapy in three patients with chronic HIV infection, Ann. Intern. Med. source
boostedstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
60 more claims · 17 with their cited sources checked
Create a free account to see all 209 claims and to verify the 40 references still open.
- It may state two separate claims as one. 103
- Probably not a substantial claim. 64
- The quote only partly states this claim. 2
Citations
Cites
CRISPR Provides Acquired Resistance Against Viruses in Prokaryotes
Barrangou, R., Fremaux, C., Deveau, H., Richards, M., Boyaval, P., Moineau, S., Romero, D. A., & Horvath, P. (2007) · Science · doi:10.1126/science.1138140 · Cited by 5,947 · cited 1×
“As has an exceptionally conserved genome, it is a HTLV-1 has an exceptionally conserved genome, it is a promising candidate for the sequence-specific and highly potent RNAi. promising candidate for the sequence-spe-ci fi c and highly potent RNAi.”
BackgroundPoiesz, B. J., Ruscetti, F. W., Gazdar, A. F., Bunn, P. A., Minna, J. D., & Gallo, R. C. (1980) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.77.12.7415 · Cited by 5,043 · cited 2×
“Multiple animal models are available, including mice, rats, rabbits, and non-human primates (NHPs).”
BackgroundHigh-Frequency off-Target Mutagenesis Induced by CRISPR-Cas Nucleases in Human Cells
Fu, Y., Foden, J. A., Khayter, C., Maeder, M. L., Reyon, D., Joung, J. K., & Sander, J. D. (2013) · Nature Biotechnology · doi:10.1038/nbt.2623 · Cited by 3,292 · cited 1×
“…hairpin RNA; RISC, RNA-induced silencing complex; RITS, RNA-induced transcriptional silencing complex; TRBP, transactivating response (TAR) RNA-binding protein; TNRC6, trinucleotide repeat containing 6 protein faily. mediated by the RITS complex, acting through repressive epigenetic modifications.”
BackgroundEvidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles
Davis, M. E., Zuckerman, J. E., Choi, C. H. J., Seligson, D., Tolcher, A., Alabi, C. A., Yen, Y., Heidel, J. D., & Ribas, A. (2010) · Nature · doi:10.1038/nature08956 · Cited by 2,505
Hinuma, Y., Nagata, K., Hanaoka, M., Nakai, M., Matsumoto, T., Kinoshita, K. I., Shirakawa, S., & Miyoshi, I. (1981) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.78.10.6476 · Cited by 2,252
A severe combined immunodeficiency mutation in the mouse
Bosma, G. C., Custer, R. P., & Bosma, M. J. (1983) · Nature · doi:10.1038/301527a0 · Cited by 2,207 · cited 1×
“Other NHPs susceptible to HTLV-1 infection include squirrel monkeys, cynomolgus monkeys, and rhesus macaques.”
BackgroundYoshida, M., Miyoshi, I., & Hinuma, Y. (1982) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.79.6.2031 · Cited by 2,169 · cited 2×
“Over the past three decades, a variety of animal models have been developed to help elucidate the events of HTLV-1 pathogenesis and evaluate novel therapeutics.”
BackgroundViral RNA-dependent DNA Polymerase: RNA-dependent DNA Polymerase in Virions of Rous Sarcoma Virus
TEMIN, H. M., & MIZUTANI, S. (1970) · Nature · doi:10.1038/2261211a0 · Cited by 2,128
Finzi, D., Blankson, J., Siliciano, J. D., Margolick, J. B., Chadwick, K., Pierson, T., Smith, K., Lisziewicz, J., Lori, F., Flexner, C., et al. (1999) · Nature Medicine · doi:10.1038/8394 · Cited by 2,119 · cited 1×
“…in endemic areas who present with associated diseases such as Sjogren’s syndrome, thyroiditis, pulmonary disease, and opportunistic infections will bene fi t from anti-HTLV-1 antibody testing, and screening should be recommended in clinics for sexually transmi tt ed infections. disease development.”
BackgroundViral RNA-dependent DNA Polymerase: RNA-dependent DNA Polymerase in Virions of RNA Tumour Viruses
BALTIMORE, D. (1970) · Nature · doi:10.1038/2261209a0 · Cited by 2,068 · cited 1×
“Detected in 1980 [1,2] through the isolation of T-lymphoblastoid cell lines, human T cell leukaemia virus type-1 (HTLV-1) became the first discovered oncogenic retrovirus, following the characterisation of reverse transcriptase in 1970 [3,4].”
BackgroundInfluentialRational design of cationic lipids for siRNA delivery
Semple, S. C., Akinc, A., Chen, J., Sandhu, A. P., Mui, B. L., Cho, C. K., Sah, D. W. Y., Stebbing, D., Crosley, E. J., Yaworski, E., et al. (2010) · Nature Biotechnology · doi:10.1038/nbt.1602 · Cited by 1,822
Fatality in mice due to oversaturation of cellular microRNA/short hairpin RNA pathways
Grimm, D., Streetz, K. L., Jopling, C. L., Storm, T. A., Pandey, K., Davis, C. R., Marion, P., Salazar, F., & Kay, M. A. (2006) · Nature · doi:10.1038/nature04791 · Cited by 1,677 · cited 2×
“The first anti-HIV-1, siPromA, was first identified in 2005 [309], and targeted the unique and highly conserved NK-κ B transcription factor sites in the HIV-1 promoter to induce potent epigenetic silencing [70,310–312].”
BackgroundShimoyama, M., & members of The Lymphoma Study Group (1984–87) (1991) · British Journal of Haematology · doi:10.1111/j.1365-2141.1991.tb08051.x · Cited by 1,608
The CRISPR tool kit for genome editing and beyond
Adli, M. (2018) · Nature Communications · doi:10.1038/s41467-018-04252-2 · Cited by 1,545 · cited 1×
“Ago1, Argonaute 1; Ago2, Argonaute 2; shRNA, short hairpin RNA; RISC, RNA-induced silencing complex; RITS, RNA-induced transcriptional silencing complex; TRBP, Created in BioRender. transactivating response (TAR”
BackgroundSeiki, M., Hattori, S., Hirayama, Y., & Yoshida, M. (1983) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.80.12.3618 · Cited by 1,525 · cited 13×
“Integrase; DNA provirus integration [30] Virion [33] here are also two regulatory proteins, Tax and Rex, which are trans-activators of transcription, the inhibition of which by the HTLV-1 p30II viral protein inhibits virus expression and suppresses Tax/HBZ-induced oxidative and metabolic toxicity [57,58].”
BackgroundInfluentialEpidemiological Aspects and World Distribution of HTLV-1 Infection
Gessain, A., & Cassar, O. (2012) · Frontiers in Microbiology · doi:10.3389/fmicb.2012.00388 · Cited by 1,428 · cited 3×
“…points, the seroprevalence of HTLV-1 in adults ranges from 0.1% to up to 40%, increasing with age and in people assigned female at birth [23–26]. focal points the seroprevalence of HTLV-1 in adults ranges from 0.1% to up to 40%, increasing with age and in people assigned female at birth [23–26].”
BackgroundInfluentialGene Editing of CCR5 in Autologous CD4 T Cells of Persons Infected with HIV
Tebas, P., Stein, D., Tang, W. W., Frank, I., Wang, S. Q., Lee, G., Spratt, S. K., Surosky, R. T., Giedlin, M. A., Nichol, G., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1300662 · Cited by 1,357 · cited 1×
“The siRNA binds to an Argonaute protein (Ago2), forming the RNA-induced silencing complex (RISC), which degrades the complementary mRNA.”
BackgroundActive human immunodeficiency virus protease is required for viral infectivity
Kohl, N. E., Emini, E. A., Schleif, W. A., Davis, L. J., Heimbach, J. C., Dixon, R. A., Scolnick, E. M., & Sigal, I. S. (1988) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.85.13.4686 · Cited by 1,307 · cited 1×
“Integrase; DNA provirus integration [30] Virion [33] here are also two regulatory proteins, Tax and Rex, which are trans-activators of transcription, the inhibition of which by the HTLV-1 p30II viral protein inhibits virus expression and suppresses Tax/HBZ-induced oxidative and metabolic toxicity…”
BackgroundTransfer of a functional human immune system to mice with severe combined immunodeficiency
Mosier, D. E., Gulizia, R. J., Baird, S. M., & Wilson, D. B. (1988) · Nature · doi:10.1038/335256a0 · Cited by 1,255 · cited 1×
“Other NHPs susceptible to HTLV-1 infection include squirrel monkeys, cynomolgus monkeys, and rhesus macaques.”
BackgroundMultiple defects in innate and adaptive immunologic function in NOD/LtSz- scid mice.
Shultz, L. D., Schweitzer, P. A., Christianson, S. W., Gott, B., Schweitzer, I. B., Tennent, B., McKenna, S., Mobraaten, L., Rajan, T. V., Greiner, D. L., et al. (1995) · The Journal of Immunology · doi:10.4049/jimmunol.154.1.180 · Cited by 1,223 · cited 1×
“NHPs indeed recapitulate most aspects of viral infection, replication, and pathogenesis; however, the high cost of research and regulations underpin its scarce use in experimental research.”
BackgroundSmall Interfering RNA-Induced Transcriptional Gene Silencing in Human Cells
Morris, K. V., Chan, S. W.-L., Jacobsen, S. E., & Looney, D. J. (2004) · Science · doi:10.1126/science.1101372 · Cited by 925 · cited 6×
“LRAs are commonly investigated for the treatment of HIV-1 and exert their action by activating viral transcription for infected cells and then “kill” reservoir cells through cytopathic mechanisms, the host immune response, or other targeted means.”
InfluentialSelf-citationRaal, F. J., Santos, R. D., Blom, D. J., Marais, A. D., Charng, M.-J., Cromwell, W. C., Lachmann, R. H., Gaudet, D., Tan, J. L., Chasan-Taber, S., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60284-x · Cited by 924 · cited 1×
“Such a vaccine for HTLV-1 could be distributed to at-risk populations in endemic regions.”
BackgroundHuman memory T cells: generation, compartmentalization and homeostasis
Farber, D. L., Yudanin, N. A., & Restifo, N. P. (2014) · Nature Reviews Immunology · doi:10.1038/nri3567 · Cited by 897 · cited 1×
“…in endemic areas who present with associated diseases such as Sjogren’s syndrome, thyroiditis, pulmonary disease, and opportunistic infections will bene fi t from anti-HTLV-1 antibody testing, and screening should be recommended in clinics for sexually transmi tt ed infections. disease development.”
BackgroundYoshida, M., Seiki, M., Yamaguchi, K., & Takatsuki, K. (1984) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.81.8.2534 · Cited by 891 · cited 1×
“HTLV-1 was first identified as the aetiologic agent of adult T cell lymphoma/leukaemia (ATL) [10], with the prevalence of 5% amongst carriers [11,12].”
BackgroundHuman T-cell leukaemia virus type 1 (HTLV-1) infectivity and cellular transformation
Matsuoka, M., & Jeang, K.-T. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2111 · Cited by 829 · cited 2×
“Overexpression of Hbz was observed to prevent Tax-induced NF-κ B and PRC2 activation, shedding light on the co-modulatory interplay of Tax and Hbz [157].”
BackgroundMontaner, J. S. G., Reiss, P., Cooper, D., Vella, S., Harris, M., Conway, B., Wainberg, M. A., Smith, D., Robinson, P., Hall, D., et al. (1998) · JAMA · doi:10.1001/jama.279.12.930 · Cited by 756 · cited 1×
“However, previous studies have characterised the potential of synthetic peptides which interfere with conformational changes in TM subunits, inhibiting env-mediated membrane fusion and HTLV-1 entry.”
BackgroundSpread of HTLV-I Between Lymphocytes by Virus-Induced Polarization of the Cytoskeleton
Igakura, T., Stinchcombe, J. C., Goon, P. K. C., Taylor, G. P., Weber, J. N., Griffiths, G. M., Tanaka, Y., Osame, M., & Bangham, C. R. M. (2003) · Science · doi:10.1126/science.1080115 · Cited by 755
Nagai, M., Usuku, K., Matsumoto, W., Kodama, D., Takenouchi, N., Moritoyo, T., Hashiguchi, S., Ichinose, M., Bangham, C. R., Izumo, S., et al. (1998) · Journal of Neurovirology · doi:10.3109/13550289809114225 · Cited by 694
Human T-lymphotropic virus 1: recent knowledge about an ancient infection
Verdonck, K., González, E., Van Dooren, S., Vandamme, A.-M., Vanham, G., & Gotuzzo, E. (2007) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(07)70081-6 · Cited by 661 · cited 1×
“HTLV-1 is a type of Deltaretrovirus, belonging to the Orthoretrovirinae subfamily, and causes life-long infection [5] in an estimated 10 million individuals worldwide across a vast geographical area, with endemic hotspots vastly limited to Indigenous populations [6–9].”
BackgroundIshida, T., Joh, T., Uike, N., Yamamoto, K., Utsunomiya, A., Yoshida, S., Saburi, Y., Miyamoto, T., Takemoto, S., Suzushima, H., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.37.3472 · Cited by 657 · cited 1×
“Treatments for HTLV-1-associated diseases and infection.”
Patisiran: First Global Approval
Hoy, S. M. (2018) · Drugs · doi:10.1007/s40265-018-0983-6 · Cited by 614
Jacobson, S., Shida, H., McFarlin, D. E., Fauci, A. S., & Koenig, S. (1990) · Nature · doi:10.1038/348245a0 · Cited by 613 · cited 1×
“Treatments for HTLV-1-associated diseases and infection.”
Scacheri, P. C., Rozenblatt-Rosen, O., Caplen, N. J., Wolfsberg, T. G., Umayam, L., Lee, J. C., Hughes, C. M., Shanmugam, K. S., Bhattacharjee, A., Meyerson, M., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0308698100 · Cited by 613 · cited 2×
“The first anti-HIV-1, siPromA, was first identified in 2005 [309], and targeted the unique and highly conserved NK-κ B transcription factor sites in the HIV-1 promoter to induce potent epigenetic silencing [70,310–312].”
BackgroundFDA-Approved Oligonucleotide Therapies in 2017
Stein, C. A., & Castanotto, D. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2017.03.023 · Cited by 608
HTLV-I basic leucine zipper factor gene mRNA supports proliferation of adult T cell leukemia cells
Satou, Y., Yasunaga, J.-I., Yoshida, M., & Matsuoka, M. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0507631103 · Cited by 593
Isolation and Transmission of Human Retrovirus (Human T-Cell Leukemia Virus)
Popovic, M., Sarin, P. S., Robert-Gurroff, M., Kalyanaraman, V. S., Mann, D., Minowada, J., & Gallo, R. C. (1983) · Science · doi:10.1126/science.6600519 · Cited by 559 · cited 2×
“Over the past three decades, a variety of animal models have been developed to help elucidate the events of HTLV-1 pathogenesis and evaluate novel therapeutics.”
BackgroundLumasiran, an RNAi Therapeutic for Primary Hyperoxaluria Type 1
Garrelfs, S. F., Frishberg, Y., Hulton, S. A., Koren, M. J., O’Riordan, W. D., Cochat, P., Deschênes, G., Shasha-Lavsky, H., Saland, J. M., van’t Hoff, W. G., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2021712 · Cited by 531
CRISPR/Cas system: recent advances and future prospects for genome editing
Manghwar, H., Lindsey, K., Zhang, X., & Jin, S. (2019) · Trends in Plant Science · doi:10.1016/j.tplants.2019.09.006 · Cited by 529 · cited 1×
“…hairpin RNA; RISC, RNA-induced silencing complex; RITS, RNA-induced transcriptional silencing complex; TRBP, transactivating response (TAR) RNA-binding protein; TNRC6, trinucleotide repeat containing 6 protein faily. mediated by the RITS complex, acting through repressive epigenetic modifications.”
BackgroundThe pX protein of HTLV-I is a transcriptional activator of its long terminal repeats
Felber, B. K., Paskalis, H., Kleinman-Ewing, C., Wong-Staal, F., & Pavlakis, G. N. (1985) · Science · doi:10.1126/science.2992082 · Cited by 516 · cited 2×
“…[31] CA Capsid [30] Virion [31] NC Nucleocapsid [30] Virion [31] Pro PR Protease; cleavage of Gag and Pol [32] Virion [32] Pol RT Reverse Transcriptase; reverse transcription of HTLV-1 RNA into DNA [30] Virion [33] RH RT-RNase H; mediates RNA cleavage during replication and repair [30] Virion [33]”
BackgroundMethodThe tat Gene of Human T-Lymphotropic Virus Type 1 Induces Mesenchymal Tumors in Transgenic Mice
Nerenberg, M., Hinrichs, S. H., Reynolds, R. K., Khoury, G., & Jay, G. (1987) · Science · doi:10.1126/science.2888190 · Cited by 510 · cited 2×
“Overexpression of Hbz was observed to prevent Tax-induced NF-κ B and PRC2 activation, shedding light on the co-modulatory interplay of Tax and Hbz [157].”
BackgroundGaudray, G., Gachon, F., Basbous, J., Biard-Piechaczyk, M., Devaux, C., & Mesnard, J.-M. (2002) · Journal of Virology · doi:10.1128/jvi.76.24.12813-12822.2002 · Cited by 506
Infective dermatitis of Jamaican children: a marker for HTLV-I infection
Blattner, W., LaGrenade, L., Hanchard, B., Fletcher, V., & Cranston, B. (1990) · The Lancet · doi:10.1016/0140-6736(90)92896-p · Cited by 453 · cited 1×
“Cont.”
In vivo cellular tropism of human T-cell leukemia virus type 1
Richardson, J. H., Edwards, A. J., Cruickshank, J. K., Rudge, P., & Dalgleish, A. G. (1990) · Journal of Virology · doi:10.1128/jvi.64.11.5682-5687.1990 · Cited by 429 · cited 1×
“As the virus predominately affects host immune cells causing subclinical immune suppression, HTLV-1 infection is also linked with an elevated rate of opportunistic infections.”
BackgroundWilley, R. L., Bonifacino, J. S., Potts, B. J., Martin, M. A., & Klausner, R. D. (1988) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.85.24.9580 · Cited by 428
Zuckerman, J. E., Gritli, I., Tolcher, A., Heidel, J. D., Lim, D., Morgan, R., Chmielowski, B., Ribas, A., Davis, M. E., & Yen, Y. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1411393111 · Cited by 427
Scott, L. J. (2020) · Drugs · doi:10.1007/s40265-020-01269-0 · Cited by 420
Jeffery, K. J. M., Usuku, K., Hall, S. E., Matsumoto, W., Taylor, G. P., Procter, J., Bunce, M., Ogg, G. S., Welsh, K. I., Weber, J. N., et al. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.7.3848 · Cited by 419 · cited 1×
“The CRISPR/Cas9 editing approach has demonstrated some success in targeting HIV-1 in vitro and in vivo [295,296], the most promising of which is a proof-of-concept study observing effective elimination of proviral DNA in infected mice [297], but this result has yet to be replicated in HTLV-1.”
BackgroundAdams, D., Tournev, I. L., Taylor, M. S., Coelho, T., Planté-Bordeneuve, V., Berk, J. L., González-Duarte, A., Gillmore, J. D., Low, S.-C., Sekijima, Y., et al. (2023) · Amyloid · doi:10.1080/13506129.2022.2091985 · Cited by 406
Spina, C. A., Anderson, J., Archin, N. M., Bosque, A., Chan, J., Famiglietti, M., Greene, W. C., Kashuba, A., Lewin, S. R., Margolis, D. M., et al. (2013) · PLoS Pathogens · doi:10.1371/journal.ppat.1003834 · Cited by 403 · cited 2×
“The vaccine was delivered in a dairy herd in Argentina and conferred immunity in 28 out of 29 cows over a 4-year period.”
BackgroundYamamoto, N., Okada, M., Koyanagi, Y., Kannagi, M., & Hinuma, Y. (1982) · Science · doi:10.1126/science.6980467 · Cited by 398
Polycation-siRNA nanoparticles can disassemble at the kidney glomerular basement membrane
Zuckerman, J. E., Choi, C. H. J., Han, H., & Davis, M. E. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1200718109 · Cited by 372
Development of leukemia in mice transgenic for the tax gene of human T-cell leukemia virus type I.
Grossman, W. J., Kimata, J. T., Wong, F. H., Zutter, M., Ley, T. J., & Ratner, L. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.4.1057 · Cited by 363
(2003) · PubMed · Cited by 355
Ray, K. K., Troquay, R. P. T., Visseren, F. L. J., Leiter, L. A., Scott Wright, R., Vikarunnessa, S., Talloczy, Z., Zang, X., Maheux, P., Lesogor, A., et al. (2023) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(22)00353-9 · Cited by 328
Yoshie, O., Fujisawa, R., Nakayama, T., Harasawa, H., Tago, H., Izawa, D., Hieshima, K., Tatsumi, Y., Matsushima, K., Hasegawa, H., et al. (2002) · Blood · doi:10.1182/blood.v99.5.1505 · Cited by 326 · cited 1×
“Treatments for HTLV-1-associated diseases and infection.”
Salahuddin, S. Z., Markhamt, P. D., Wong-staal, F., Franchini, G., Kalyanaraman, V. S., & Gallo, R. C. (1983) · Virology · doi:10.1016/0042-6822(83)90395-1 · Cited by 324 · cited 1×
“Multiple animal models are available, including mice, rats, rabbits, and non-human primates (NHPs).”
BackgroundHTLV-1 bZIP Factor Induces T-Cell Lymphoma and Systemic Inflammation In Vivo
Satou, Y., Yasunaga, J.-I., Zhao, T., Yoshida, M., Miyazato, P., Takai, K., Shimizu, K., Ohshima, K., Green, P. L., Ohkura, N., et al. (2011) · PLoS Pathogens · doi:10.1371/journal.ppat.1001274 · Cited by 319 · cited 1×
“Overexpression of Hbz was observed to prevent Tax-induced NF-κ B and PRC2 activation, shedding light on the co-modulatory interplay of Tax and Hbz [157].”
BackgroundMoulard, M., Lortat-Jacob, H., Mondor, I., Roca, G., Wyatt, R., Sodroski, J., Zhao, L., Olson, W., Kwong, P. D., & Sattentau, Q. J. (2000) · Journal of Virology · doi:10.1128/jvi.74.4.1948-1960.2000 · Cited by 297
Sequential LASER ART and CRISPR Treatments Eliminate HIV-1 in a Subset of Infected Humanized Mice
Dash, P. K., Kaminski, R., Bella, R., Su, H., Mathews, S., Ahooyi, T. M., Chen, C., Mancuso, P., Sariyer, R., Ferrante, P., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-10366-y · Cited by 295 · cited 1×
“21 of 40 This was addressed using viral delivery methods to provide long-term siRNA expression, but this solution does not come without its caveats, as the over-saturation of cellular machinery may pose risks of toxicity and o ff -target e ff ects [304–306]. thereby silencing gene expression [303]…”
BackgroundHidaka, M., Inoue, J., Yoshida, M., & Seiki, M. (1988) · The EMBO Journal · doi:10.1002/j.1460-2075.1988.tb02840.x · Cited by 280
Yamano, Y., Nagai, M., Brennan, M., Mora, C. A., Soldan, S. S., Tomaru, U., Takenouchi, N., Izumo, S., Osame, M., & Jacobson, S. (2002) · Blood · doi:10.1182/blood.v99.1.88 · Cited by 279 · cited 1×
“The majority of discourse surrounds the introduction of breaks along the tax and hbz viral genes, interrupting im-mortalisation and suppressing infected cell growth and survival.”
BackgroundChun, T.-W., Justement, J. S., Murray, D., Hallahan, C. W., Maenza, J., Collier, A. C., Sheth, P. M., Kaul, R., Ostrowski, M., Moir, S., et al. (2010) · AIDS · doi:10.1097/qad.0b013e328340a239 · Cited by 276
Ishida, T., Jo, T., Takemoto, S., Suzushima, H., Uozumi, K., Yamamoto, K., Uike, N., Saburi, Y., Nosaka, K., Utsunomiya, A., et al. (2015) · British Journal of Haematology · doi:10.1111/bjh.13338 · Cited by 267 · cited 1×
“Treatments for HTLV-1-associated diseases and infection.”
Revised Adult T-Cell Leukemia-Lymphoma International Consensus Meeting Report
Cook, L. B., Fuji, S., Hermine, O., Bazarbachi, A., Ramos, J. C., Ratner, L., Horwitz, S., Fields, P., Tanase, A., Bumbea, H., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.18.00501 · Cited by 267 · cited 4×
“Lesser-known medical burdens of HTLV-1 infection extend beyond this list, as patients report experiencing non-specific neuropathic/non-neuropathic pain alongside infection [262].”
BackgroundResultInfluentialTwo types of defective human T-lymphotropic virus type I provirus in adult T-cell leukemia
Tamiya, S., Matsuoka, M., Etoh, K., Watanabe, T., Kamihira, S., Yamaguchi, K., & Takatsuki, K. (1996) · Blood · doi:10.1182/blood.v88.8.3065.bloodjournal8883065 · Cited by 263 · cited 1×
“Clinically vulnerable patient populations in endemic areas who present with associated diseases such as Sjogren’s syndrome, thyroiditis, pulmonary disease, and opportunistic infections will benefit from anti-HTLV-1 antibody testing, and screening should be recommended in clinics for sexually…”
BackgroundA Transgenic Mouse Model for Human Neurofibromatosis
Hinrichs, S. H., Nerenberg, M., Reynolds, R. K., Khoury, G., & Jay, G. (1987) · Science · doi:10.1126/science.2888191 · Cited by 261 · cited 1×
“HTLV-1 transgenic flies, Drosophila melanogaster, expressing Tax and Hbz were proposed to study Tax-driven oncogenesis in vivo [156,157].”
BackgroundMocroft, A., Phillips, A., Gatell, J., Ledergerber, B., Fisher, M., Clumeck, N., Losso, M., Lazzarin, A., Fatkenheuer, G., & Lundgren, J. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60948-9 · Cited by 259 · cited 1×
“NNRTIs are non-competitive inhibitors of RT, binding instead at an allosteric pocket and altering the structural conformation of the binding site [176].”
BackgroundBoxus, M., Twizere, J.-C., Legros, S., Dewulf, J.-F., Kettmann, R., & Willems, L. (2008) · Retrovirology · doi:10.1186/1742-4690-5-76 · Cited by 255
Kannagi, M., Harada, S., Maruyama, I., Inoko, H., Igarashi, H., Kuwashima, G., Sato, S., Morita, M., Kidokoro, M., Sugimoto, M., et al. (1991) · International Immunology · doi:10.1093/intimm/3.8.761 · Cited by 253 · cited 1×
“Treatments for HTLV-1-associated diseases and infection.”
Schierhout, G., McGregor, S., Gessain, A., Einsiedel, L., Martinello, M., & Kaldor, J. (2020) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(19)30402-5 · Cited by 250 · cited 1×
“Since its discovery, further characterisation has suggested that HTLV-1 carries a much broader burden of disease globally, being implicated in a range of immune-associated diseases and systemic inflammation, amongst other comorbidities [13–17].”
BackgroundExosomes as a Nanodelivery System: a Key to the Future of Neuromedicine?
Aryani, A., & Denecke, B. (2016) · Molecular Neurobiology · doi:10.1007/s12035-014-9054-5 · Cited by 238 · cited 1×
“Along with the novelty of siRNA therapeutics, there are still many challenges posed for the literature to address, including efficient and targeted delivery and clinical translation.”
BackgroundKoiwa, T., Hamano-Usami, A., Ishida, T., Okayama, A., Yamaguchi, K., Kamihira, S., & Watanabe, T. (2002) · Journal of Virology · doi:10.1128/jvi.76.18.9389-9397.2002 · Cited by 235 · cited 1×
“There is an urgent need for expanded screening for HTLV-1 infection in asymptomatic carriers who can benefit from clinical monitoring.”
BackgroundProgress and prospects: Zinc-finger nucleases as gene therapy agents
Carroll, D. (2008) · Gene Therapy · doi:10.1038/gt.2008.145 · Cited by 225 · cited 1×
“The siRNA binds to an Argonaute protein (Ago2), forming the RNA-induced silencing complex (RISC), which degrades the complementary mRNA.”
BackgroundThe GAG precursor of simian immunodeficiency virus assembles into virus-like particles.
Delchambre, M., Gheysen, D., Thines, D., Thiriart, C., Jacobs, E., Verdin, E., Horth, M., Burny, A., & Bex, F. (1989) · The EMBO Journal · doi:10.1002/j.1460-2075.1989.tb08405.x · Cited by 224 · cited 1×
“Integrase; DNA provirus integration [30] Virion [33] here are also two regulatory proteins, Tax and Rex, which are trans-activators of transcription, the inhibition of which by the HTLV-1 p30II viral protein inhibits virus expression and suppresses Tax/HBZ-induced oxidative and metabolic toxicity…”
BackgroundJeffery, K. J. M., Siddiqui, A. A., Bunce, M., Lloyd, A. L., Vine, A. M., Witkover, A. D., Izumo, S., Usuku, K., Welsh, K. I., Osame, M., et al. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.165.12.7278 · Cited by 222 · cited 1×
“The CRISPR/Cas9 editing approach has demonstrated some success in targeting HIV-1 in vitro and in vivo [295,296], the most promising of which is a proof-of-concept study observing effective elimination of proviral DNA in infected mice [297], but this result has yet to be replicated in HTLV-1.”
BackgroundA novel T-cell line derived from adult T-cell leukemia.
Miyoshi, I., Kubonishi, I., Sumida, M., Hiraki, S., Tsubota, T., Kimura, I., Miyamoto, K., & Sato, J. (1980) · PubMed · Cited by 221
A novel T-cell line derived from adult T-cell leukemia.
Miyoshi, I., Kubonishi, I., Sumida, M., Hiraki, S., Tsubota, T., Kimura, I., Miyamoto, K., & Sato, J. (1980) · Gan · doi:10.20772/cancersci1959.71.1_155 · Cited by 217
The Challenges and Strategies of Antisense Oligonucleotide Drug Delivery
Gagliardi, M., & Ashizawa, A. T. (2021) · Biomedicines · doi:10.3390/biomedicines9040433 · Cited by 210 · cited 1×
“Such a vaccine for HTLV-1 could be distributed to at-risk populations in endemic regions.”
BackgroundSilencing of human T-cell leukemia virus type I gene transcription by epigenetic mechanisms
Taniguchi, Y., Nosaka, K., Yasunaga, J.-I., Maeda, M., Mueller, N., Okayama, A., & Matsuoka, M. (2005) · Retrovirology · doi:10.1186/1742-4690-2-64 · Cited by 209
Human T-cell leukemia virus type-1 antisense-encoded gene, Hbz, promotes T-lymphocyte proliferation
Arnold, J., Zimmerman, B., Li, M., Lairmore, M. D., & Green, P. L. (2008) · Blood · doi:10.1182/blood-2008-04-154286 · Cited by 207
Human T-Lymphotropic Virus Type I (HTLV-I) Seroprevalence in Jamaica
Murphy, E., Figueroa, P., Gibbs, W. N., Holding-Cobham, M., Cranston, B., Malley, K., Bodner, A. J., Alexander, S. S., & Blattner, W. A. (1991) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a115824 · Cited by 199
Fuji, S., Inoue, Y., Utsunomiya, A., Moriuchi, Y., Uchimaru, K., Choi, I., Otsuka, E., Henzan, H., Kato, K., Tomoyose, T., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.67.8250 · Cited by 197 · cited 1×
“Treatments for HTLV-1-associated diseases and infection.”
Arnold, J., Yamamoto, B., Li, M., Phipps, A. J., Younis, I., Lairmore, M. D., & Green, P. L. (2006) · Blood · doi:10.1182/blood-2005-11-4551 · Cited by 196
HIV‐1 NNRTIs: structural diversity, pharmacophore similarity, and impliations for drug design
Zhan, P., Chen, X., Li, D., Fang, Z., De Clercq, E., & Liu, X. (2013) · Medicinal Research Reviews · doi:10.1002/med.20241 · Cited by 192 · cited 1×
“The crystal structure of HTLV-1 PR was recently characterised [189] (Protein data bank code 3WSJ) and bore highly similar three-dimensional folding to HIV-1 PR, despite only sharing 26% amino acid sequence identity and 38% amino acid sequence similarity [73].”
BackgroundZhang, K., Zheludev, I. N., Hagey, R. J., Haslecker, R., Hou, Y. J., Kretsch, R., Pintilie, G. D., Rangan, R., Kladwang, W., Li, S., et al. (2021) · Nature Structural & Molecular Biology · doi:10.1038/s41594-021-00653-y · Cited by 189 · cited 1×
“Such a vaccine for HTLV-1 could be distributed to at-risk populations in endemic regions.”
BackgroundSaito, M., Matsuzaki, T., Satou, Y., Yasunaga, J.-I., Saito, K., Arimura, K., Matsuoka, M., & Ohara, Y. (2009) · Retrovirology · doi:10.1186/1742-4690-6-19 · Cited by 184 · cited 1×
“As HTLV-1 is highly genetically conserved within hosts and among isolates, it serves as a powerful candidate for focused gRNA targeting and generalised gene manipulation approaches.”
BackgroundThe Molecular Basis for Human Immunodeficiency Virus Latency
Mbonye, U., & Karn, J. (2017) · Annual Review of Virology · doi:10.1146/annurev-virology-101416-041646 · Cited by 182 · cited 1×
“Disease progression of HTLV-1 and the rates of infection.”
BackgroundAzimi, N., Brown, K., Bamford, R. N., Tagaya, Y., Siebenlist, U., & Waldmann, T. A. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.5.2452 · Cited by 181
Existence of escape mutant in HTLV-I tax during the development of adult T-cell leukemia
Furukawa, Y., Kubota, R., Tara, M., Izumo, S., & Osame, M. (2001) · Blood · doi:10.1182/blood.v97.4.987 · Cited by 181
Infecção e doença pelos vírus linfotrópicos humanos de células T (HTLV-I/II) no Brasil
Carneiro‐Proietti, A. B. F., Ribas, J. G., Catalan-Soares, B. C., Martins, M. L., de Melo, G. E. B. A., Martins‐Filho, O. A., Pinheiro, S. R., Araújo, A., Galvão‐Castro, B., Pombo‐de‐Oliveira, M. S., et al. (2002) · Revista da Sociedade Brasileira de Medicina Tropical · doi:10.1590/s0037-86822002000500013 · Cited by 180
Maeda, M., Shimizu, A., Ikuta, K., Okamoto, H., Kashihara, M., Uchiyama, T., Honjo, T., & Yodoi, J. (1985) · The Journal of experimental medicine · doi:10.1084/jem.162.6.2169 · Cited by 180 · cited 1×
“HTLV-1 does not productively infect murine cells and must be first inoculated to establish persistent infection.”
BackgroundLong-term study of indolent adult T-cell leukemia-lymphoma
Takasaki, Y., Iwanaga, M., Imaizumi, Y., Tawara, M., Joh, T., Kohno, T., Yamada, Y., Kamihira, S., Ikeda, S., Miyazaki, Y., et al. (2010) · Blood · doi:10.1182/blood-2009-09-242347 · Cited by 180 · cited 1×
“Previous sections have outlined the lack of specific and targeted treatments for HTLV-1 inflammatory and immune related conditions, which is mirrored in the treatment of other associated inflammatory diseases and secondary infections.”
BackgroundMahgoub, M., Yasunaga, J.-I., Iwami, S., Nakaoka, S., Koizumi, Y., Shimura, K., & Matsuoka, M. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1715724115 · Cited by 177 · cited 1×
“Treatments for HTLV-1-associated diseases and infection.”
Increased replication of HTLV‐I in HTLV‐I–associated myelopathy
Yoshida, M., Osame, M., Kawai, H., Toita, M., Kuwasaki, N., Nishida, Y., Hiraki, Y., Takahashi, K., Nomura, K., Sonoda, S., et al. (1989) · Annals of Neurology · doi:10.1002/ana.410260304 · Cited by 176
The use of plasma HIV RNA as a study endpoint in efficacy trials of antiretroviral drugs
Murray, J. S., Elashoff, M. R., Iacono-Connors, L. C., Cvetkovich, T. A., & Struble, K. A. (1999) · AIDS · doi:10.1097/00002030-199905070-00008 · Cited by 174 · cited 1×
“NNRTIs are non-competitive inhibitors of RT, binding instead at an allosteric pocket and altering the structural conformation of the binding site [176].”
BackgroundManns, A., & Blattner, W. A. (1991) · Transfusion · doi:10.1046/j.1537-2995.1991.31191096189.x · Cited by 174 · cited 2×
“[28].”
BackgroundLi, H., Biggar, R. J., Miley, W. J., Maloney, E. M., Cranston, B., Hanchard, B., & Hisada, M. (2004) · The Journal of Infectious Diseases · doi:10.1086/423941 · Cited by 171
p27x-III and p21x-III, proteins encoded by the pX sequence of human T-cell leukemia virus type I.
Kiyokawa, T., Seiki, M., Iwashita, S., Imagawa, K., Shimizu, F., & Yoshida, M. (1985) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.82.24.8359 · Cited by 169
Izutsu, K., Makita, S., Nosaka, K., Yoshimitsu, M., Utsunomiya, A., Kusumoto, S., Morishima, S., Tsukasaki, K., Kawamata, T., Ono, T., et al. (2023) · Blood · doi:10.1182/blood.2022016862 · Cited by 167 · cited 1×
“Treatments for HTLV-1-associated diseases and infection.”
Antisense oligonucleotides: a novel Frontier in pharmacological strategy
Collotta, D., Bertocchi, I., Chiapello, E., & Collino, M. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1304342 · Cited by 167 · cited 1×
“Such a vaccine for HTLV-1 could be distributed to at-risk populations in endemic regions.”
BackgroundMatsumoto, J., Ohshima, T., Isono, O., & Shimotohno, K. (2004) · Oncogene · doi:10.1038/sj.onc.1208297 · Cited by 164
Izumo, S., Goto, I., Itoyama, Y., Okajima, T., Watanabe, S., Kuroda, Y., Araki, S., Mori, M., Nagataki, M., Matsukura, S., et al. (1996) · Neurology · doi:10.1212/wnl.46.4.1016 · Cited by 164 · cited 1×
“…Topical or systemic corticosteroids and mydriatics [263] HTLV-1-associated Sjögren’s Syndrome Artificial lubricants such as saliva/tears replacement solutions coupled with systemic pharmacotherapy with pilocarpine hydrochloride [264] HTLV-1-associated Hashimoto’s thyroiditis and Graves’ disease”
BackgroundAit-Ammar, A., Kula, A., Darcis, G., Verdikt, R., De Wit, S., Gautier, V., Mallon, P. W. G., Marcello, A., Rohr, O., & Van Lint, C. (2020) · Frontiers in Microbiology · doi:10.3389/fmicb.2019.03060 · Cited by 163 · cited 1×
“Recently, an attenuated BLV vaccine was developed that harbours a mutation in the env gene and deletions of sense and anti-sense accessory genes (AS1-S, AS1-L, R3 and G4) [350].”
BackgroundFutsch, N., Mahieux, R., & Dutartre, H. (2017) · Viruses · doi:10.3390/v10010001 · Cited by 155
Elimination Pathways of Systemically Delivered siRNA
Huang, Y., Hong, J., Zheng, S., Ding, Y., Guo, S., Zhang, H., Zhang, X., Du, Q., & Liang, Z. (2011) · Molecular Therapy · doi:10.1038/mt.2010.266 · Cited by 152
Kira, J., Koyanagi, Y., Yamada, T., Itoyama, Y., Goto, I., Yamamoto, N., Sasaki, H., & Sakaki, Y. (1991) · Annals of Neurology · doi:10.1002/ana.410290214 · Cited by 152
Ishida, T., Fujiwara, H., Nosaka, K., Taira, N., Abe, Y., Imaizumi, Y., Moriuchi, Y., Jo, T., Ishizawa, K., Tobinai, K., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.67.7732 · Cited by 152 · cited 1×
“Treatments for HTLV-1-associated diseases and infection.”
Berneman, Z. N., Gartenhaus, R. B., Reitz, M. S., Blattner, W. A., Manns, A., Hanchard, B., Ikehara, O., Gallo, R. C., & Klotman, M. E. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.7.3005 · Cited by 151
Therapeutic trials in 200 patients with HTLV-Iassociated myelopathy/tropical spastic paraparesis
Nakagawa, M., Nakahara, K., Maruyama, Y., Kawabata, M., Higuchi, I., Kubota, H., Izumo, S., Arimura, K., & Osame, M. (1996) · Journal of Neurovirology · doi:10.3109/13550289609146899 · Cited by 150
Takahashi, K., Takezaki, T., Oki, T., Kawakami, K., Yashiki, S., Fujiyoshi, T., Usuku, K., THE MOTHER‐TO‐CHILD TRANSMISSION STUDY GROUP, Mueller, N., Osame, M., et al. (1991) · International Journal of Cancer · doi:10.1002/ijc.2910490508 · Cited by 149
Inflammatory manifestations of HTLV-1 and their therapeutic options
Martin, F., Taylor, G. P., & Jacobson, S. (2014) · Expert Review of Clinical Immunology · doi:10.1586/1744666x.2014.966690 · Cited by 147 · cited 2×
“HTLV-1-associated arthritis Immunomodulatory therapies such as TNF-α [268] HTLV-1-associated conjunctivitis sicca syndrome and interstitial keratitis Artificial lubricants such as tears, cyclosporine eye drops [264] Relapse is common when treatment is halted.”
BackgroundNagai, M., Yamano, Y., Brennan, M. B., Mora, C. A., & Jacobson, S. (2001) · Annals of Neurology · doi:10.1002/ana.10065 · Cited by 144
Yamano, Y., Araya, N., Sato, T., Utsunomiya, A., Azakami, K., Hasegawa, D., Izumi, T., Fujita, H., Aratani, S., Yagishita, N., et al. (2009) · PLoS ONE · doi:10.1371/journal.pone.0006517 · Cited by 140 · cited 1×
“Treatments for HTLV-1-associated diseases and infection.”
Reducing the global burden of HTLV-1 infection: An agenda for research and action
Willems, L., Hasegawa, H., Accolla, R., Bangham, C., Bazarbachi, A., Bertazzoni, U., Carneiro-Proietti, A. B. D. F., Cheng, H., Chieco-Bianchi, L., Ciminale, V., et al. (2017) · Antiviral Research · doi:10.1016/j.antiviral.2016.10.015 · Cited by 140
Persistent inhibition of telomerase reprograms adult T-cell leukemia to p53-dependent senescence
Datta, A., Bellon, M., Sinha-Datta, U., Bazarbachi, A., Lepelletier, Y., Canioni, D., Waldmann, T. A., Hermine, O., & Nicot, C. (2006) · Blood · doi:10.1182/blood-2006-01-0067 · Cited by 139 · cited 1×
“This will be discussed further in Section 2.2.”
BackgroundInfluentialMiyazaki, M., Yasunaga, J.-I., Taniguchi, Y., Tamiya, S., Nakahata, T., & Matsuoka, M. (2007) · Journal of Virology · doi:10.1128/jvi.02511-06 · Cited by 137 · cited 1×
“Clinically vulnerable patient populations in endemic areas who present with associated diseases such as Sjogren’s syndrome, thyroiditis, pulmonary disease, and opportunistic infections will benefit from anti-HTLV-1 antibody testing, and screening should be recommended in clinics for sexually…”
BackgroundLeeansyah, E., Cameron, P. U., Solomon, A., Tennakoon, S., Velayudham, P., Gouillou, M., Spelman, T., Hearps, A., Fairley, C., Smit, D. V., et al. (2013) · The Journal of Infectious Diseases · doi:10.1093/infdis/jit006 · Cited by 136 · cited 1×
“This will be discussed further in Section 2.2.”
BackgroundInfluential(2005) · PubMed Central · Cited by 134
Self-citationFunctional and biochemical interaction of the HTLV‐I Tax1 transactivator with TBP.
Caron, C., Rousset, R., Beraud, C., Moncollin, V., Egly, J., & Jalinot, P. (1993) · The EMBO Journal · doi:10.1002/j.1460-2075.1993.tb06111.x · Cited by 134
Koralnik, I. J., Fullen, J., & Franchini, G. (1993) · Journal of Virology · doi:10.1128/jvi.67.4.2360-2366.1993 · Cited by 133
Mochizuki, M., Yamaguchi, K., Takatsuki, K., Watanabe, T., Mori, S., & Tajima, K. (1992) · The Lancet · doi:10.1016/0140-6736(92)90699-4 · Cited by 132 · cited 1×
“Cont.”
Mechanisms of action and resistance in histone methylation-targeted therapy
Yamagishi, M., Kuze, Y., Kobayashi, S., Nakashima, M., Morishima, S., Kawamata, T., Makiyama, J., Suzuki, K., Seki, M., Abe, K., et al. (2024) · Nature · doi:10.1038/s41586-024-07103-x · Cited by 131 · cited 1×
“Treatments for HTLV-1-associated diseases and infection.”
Gessain, A., Saal, F., Gout, O., Daniel, M., Flandrin, G., de The, G., Peries, J., & Sigaux, F. (1990) · Blood · doi:10.1182/blood.v75.2.428.428 · Cited by 130
Watanabe, M. (2005) · Blood · doi:10.1182/blood-2004-09-3646 · Cited by 129 · cited 1×
“Treatments for HTLV-1-associated diseases and infection.”
Usui, T., Yanagihara, K., Tsukasaki, K., Murata, K., Hasegawa, H., Yamada, Y., & Kamihira, S. (2008) · Retrovirology · doi:10.1186/1742-4690-5-34 · Cited by 127 · cited 1×
“…patient populations in endemic areas who present with associated diseases such as Sjogren’s syndrome, thyroiditis, pulmonary disease, and opportunistic infections will benefit from anti-HTLV-1 antibody testing, and screening should be recommended in clinics for sexually transmitted infections.”
BackgroundNakashima, H., Matsui, T., Harada, S., Kobayashi, N., Matsuda, A., Ueda, T., & Yamamoto, N. (1986) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.30.6.933 · Cited by 127 · cited 1×
“This will be discussed further in Section 2.2.”
BackgroundInfluentialMaier, D. A., Brennan, A. L., Jiang, S., Binder-Scholl, G. K., Lee, G., Plesa, G., Zheng, Z., Cotte, J., Carpenito, C., Wood, T., et al. (2013) · Human Gene Therapy · doi:10.1089/hum.2012.172 · Cited by 126 · cited 1×
“The siRNA binds to an Argonaute protein (Ago2), forming the RNA-induced silencing complex (RISC), which degrades the complementary mRNA.”
BackgroundOkuma, K., Nakamura, M., Nakano, S., Niho, Y., & Matsuura, Y. (1999) · Virology · doi:10.1006/viro.1998.9530 · Cited by 124
Arima, N., Molitor, J. A., Smith, M. R., Kim, J. H., Daitoku, Y., & Greene, W. C. (1991) · Journal of Virology · doi:10.1128/jvi.65.12.6892-6899.1991 · Cited by 120 · cited 3×
“Three months post infection, HTLV-1 provirus was detected in PBMCs and lymphoid organs.”
BackgroundMethodAge- and sex-specific cumulative rate and risk of ATLL for HTLV-I carriers
Kondo, T., Kono, H., Miyamoto, N., Yoshida, R., Toki, H., Matsumoto, I., Hara, M., Inoue, H., Inatsuki, A., Funatsu, T., et al. (1989) · International Journal of Cancer · doi:10.1002/ijc.2910430618 · Cited by 118 · cited 1×
“Previous sections have outlined the lack of specific and targeted treatments for HTLV-1 inflammatory and immune related conditions, which is mirrored in the treatment of other associated inflammatory diseases and secondary infections.”
BackgroundNejmeddine, M., Negi, V. S., Mukherjee, S., Tanaka, Y., Orth, K., Taylor, G. P., & Bangham, C. R. M. (2009) · Blood · doi:10.1182/blood-2008-03-136770 · Cited by 118 · cited 1×
“Treatments for HTLV-1-associated diseases and infection.”
Molecular mechanisms of HIV-1 resistance to nucleoside reverse transcriptase inhibitors (NRTIs)
Sluis-Cremer, N., Arion, D., & Parniak*, M. A. (2000) · Cellular and Molecular Life Sciences · doi:10.1007/pl00000626 · Cited by 117 · cited 1×
“The crystal structure of HTLV-1 PR was recently characterised [189] (Protein data bank code 3WSJ) and bore highly similar three-dimensional folding to HIV-1 PR, despite only sharing 26% amino acid sequence identity and 38% amino acid sequence similarity [73].”
BackgroundTaylor, G. P., Goon, P., Furukawa, Y., Green, H., Barfield, A., Mosley, A., Nose, H., Babiker, A., Rudge, P., Usuku, K., et al. (2006) · Retrovirology · doi:10.1186/1742-4690-3-63 · Cited by 117 · cited 3×
“…Topical or systemic corticosteroids and mydriatics [263] HTLV-1-associated Sjögren’s Syndrome Artificial lubricants such as saliva/tears replacement solutions coupled with systemic pharmacotherapy with pilocarpine hydrochloride [264] HTLV-1-associated Hashimoto’s thyroiditis and Graves’ disease”
BackgroundInfluentialMoura, I. C. (2004) · Blood · doi:10.1182/blood-2003-07-2440 · Cited by 114
Mogamulizumab (Anti-CCR4) in HTLV-1-Associated Myelopathy
Sato, T., Coler-Reilly, A. L. G., Yagishita, N., Araya, N., Inoue, E., Furuta, R., Watanabe, T., Uchimaru, K., Matsuoka, M., Matsumoto, N., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1704827 · Cited by 113 · cited 2×
“…Topical or systemic corticosteroids and mydriatics [263] HTLV-1-associated Sjögren’s Syndrome Artificial lubricants such as saliva/tears replacement solutions coupled with systemic pharmacotherapy with pilocarpine hydrochloride [264] HTLV-1-associated Hashimoto’s thyroiditis and Graves’ disease”
BackgroundHTLV in the Americas: challenges and perspectives
Carneiro-Proietti, A. B. F., Catalan-Soares, B. C., Castro-Costa, C. M., Murphy, E. L., Sabino, E. C., Hisada, M., Galvão-Castro, B., Alcantara, L. C. J., Remondegui, C., Verdonck, K., et al. (2006) · Revista Panamericana de Salud Pública · doi:10.1590/s1020-49892006000100007 · Cited by 111
The simian origins of the pathogenic human T-cell lymphotropic virus type I
Vandamme, A. (1998) · Trends in Microbiology · doi:10.1016/s0966-842x(98)01406-1 · Cited by 109 · cited 2×
“Due to its low sequence variation, phylogenetic studies can be used to trace the origins of HTLV-1 to Central Africa, with Africa being the only continent where all different forms of the Primate T-Lymphotropic Virus (PTLV) can be found [21,27].”
BackgroundClosed Chromatin Architecture Is Induced by an RNA Duplex Targeting the HIV-1 Promoter Region
Suzuki, K., Juelich, T., Lim, H., Ishida, T., Watanebe, T., Cooper, D. A., Rao, S., & Kelleher, A. D. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m709651200 · Cited by 108 · cited 1×
“Following previous failed attempts, including DNA vaccines that did not prevent later infection due to transient activation, including recombinant vaccinia virus (RVV) and inactivated BLV, the attenuated BLV succeeded with deletions in genes that regulate infectivity and replication [351].”
MethodSelf-citationMicrovesicles: Novel Biomarkers for Neurological Disorders
Colombo, E., Borgiani, B., Verderio, C., & Furlan, R. (2012) · Frontiers in Physiology · doi:10.3389/fphys.2012.00063 · Cited by 107 · cited 1×
“Along with the novelty of siRNA therapeutics, there are still many challenges posed for the literature to address, including efficient and targeted delivery and clinical translation.”
BackgroundCharacterization of a novel nuclear localization signal in the HTLV-I tax transactivator protein
Smith, M. R., & Greene, W. C. (1992) · Virology · doi:10.1016/0042-6822(92)90320-o · Cited by 107
Recent advances in the treatment of adult T‐cell leukemia‐lymphomas
Utsunomiya, A., Choi, I., Chihara, D., & Seto, M. (2015) · Cancer Science · doi:10.1111/cas.12617 · Cited by 103 · cited 13×
“Long-term corticosteroid therapy [265] HTLV-1-associated inflammatory myositis Currently no available therapeutic; myositis is resistant to corticosteroids and immunomodulatory therapies such as cyclosporin [266,267] Table 5.”
BackgroundInfluentialHuman T cell leukemia virus type I-induced disease: pathways to cancer and neurodegeneration
Barmak, K., Harhaj, E., Grant, C., Alefantis, T., & Wigdahl, B. (2003) · Virology · doi:10.1016/s0042-6822(02)00091-0 · Cited by 101 · cited 1×
“The CRISPR/Cas9 editing approach has demonstrated some success in targeting HIV-1 in vitro and in vivo [295,296], the most promising of which is a proof-of-concept study observing effective elimination of proviral DNA in infected mice [297], but this result has yet to be replicated in HTLV-1.”
BackgroundEinsiedel, L., Fernandes, L., Spelman, T., Steinfort, D., & Gotuzzo, E. (2012) · Clinical Infectious Diseases · doi:10.1093/cid/cir766 · Cited by 99 · cited 1×
“A caveat, however, is that immunocompetent HTLV-1 carrier mouse models demonstrate very little in vivo spread of infection with no evidence of disease, except for one report of tumorigenesis [125,126].”
BackgroundTebas, P., Jadlowsky, J. K., Shaw, P. A., Tian, L., Esparza, E., Brennan, A. L., Kim, S., Naing, S. Y., Richardson, M. W., Vogel, A. N., et al. (2021) · Journal of Clinical Investigation · doi:10.1172/jci144486 · Cited by 99
Argyris, E. G., Acheampong, E., Nunnari, G., Mukhtar, M., Williams, K. J., & Pomerantz, R. J. (2003) · Journal of Virology · doi:10.1128/jvi.77.22.12140-12151.2003 · Cited by 98 · cited 1×
“The compounds which were active in vitro reduced cell proliferation ex vivo at lower concentrations and resulted in a dramatic decrease in number of migration events and PVL in early infection.”
BackgroundKira, J.-I., Fujihara, K., Itoyama, Y., Goto, I., & Hasuo, K. (1991) · Journal of the Neurological Sciences · doi:10.1016/0022-510x(91)90192-a · Cited by 96 · cited 1×
“…Topical or systemic corticosteroids and mydriatics [263] HTLV-1-associated Sjögren’s Syndrome Artificial lubricants such as saliva/tears replacement solutions coupled with systemic pharmacotherapy with pilocarpine hydrochloride [264] HTLV-1-associated Hashimoto’s thyroiditis and Graves’ disease”
BackgroundSubramaniam, J., Whiteside, G., McKeage, K., & Croxtall, J. C. (2012) · Drugs · doi:10.2165/11631090-000000000-00000 · Cited by 96
Nuclear localization of HTLV-I bZIP factor (HBZ) is mediated by three distinct motifs
Hivin, P., Frédéric, M., Arpin-André, C., Basbous, J., Gay, B., Thébault, S., & Mesnard, J.-M. (2005) · Journal of Cell Science · doi:10.1242/jcs.01727 · Cited by 92
Exosome-mediated stable epigenetic repression of HIV-1
Shrivastava, S., Ray, R. M., Holguin, L., Echavarria, L., Grepo, N., Scott, T. A., Burnett, J., & Morris, K. V. (2021) · Nature Communications · doi:10.1038/s41467-021-25839-2 · Cited by 92 · cited 1×
“Despite these challenges, the development of RNAi therapeutics has illuminated an exciting new modality of therapy and could have considerable implications for the future of treating HTLV-1.”
BackgroundSelf-citationTanajura, D., Castro, N., Oliveira, P., Neto, A., Muniz, A., Carvalho, N. B., Orge, G., Santos, S., Glesby, M. J., & Carvalho, E. M. (2015) · Clinical Infectious Diseases · doi:10.1093/cid/civ229 · Cited by 91
Secchiero, P., Sun, D., Vico, A. L. D., Crowley, R. W., Reitz, M. S., Zauli, G., Lusso, P., & Gallo, R. C. (1997) · Journal of Virology · doi:10.1128/jvi.71.6.4571-4580.1997 · Cited by 90 · cited 1×
“The compounds which were active in vitro reduced cell proliferation ex vivo at lower concentrations and resulted in a dramatic decrease in number of migration events and PVL in early infection.”
BackgroundTsukasaki, K., Miller, C. W., Kubota, T., Takeuchi, S., Fujimoto, T., Ikeda, S., Tomonaga, M., & Koeffler, H. P. (2001) · PubMed · Cited by 90
Bazarbachi, A. A., Cwynarski, K., Boumendil, A., Finel, H., Fields, P. A., Raj, K. K., Nagler, A., Mohty, M., Sureda, A. M., Dreger, P., et al. (2014) · Bone Marrow Transplantation · doi:10.1038/bmt.2014.143 · Cited by 90 · cited 1×
“Data are scarce on the prevalence of secondary infections, with previously conducted studies being observational in nature and limited by their small cohorts and geographic restraints.”
ResultHigh prevalence of Sjögren's syndrome in patients with HTLV-I associated myelopathy
Nakamura, H., Eguchi, K., Nakamura, T., Mizokami, A., Shirabe, S., Kawakami, A., Matsuoka, N., Migita, K., Kawabe, Y., & Nagataki, S. (1997) · Annals of the Rheumatic Diseases · doi:10.1136/ard.56.3.167 · Cited by 90
Afonso, P. V., Cassar, O., & Gessain, A. (2019) · Retrovirology · doi:10.1186/s12977-019-0504-z · Cited by 90 · cited 3×
“A caveat, however, is that immunocompetent HTLV-1 carrier mouse models demonstrate very little in vivo spread of infection with no evidence of disease, except for one report of tumorigenesis [125,126].”
BackgroundBovine Leukaemia Virus: Current Epidemiological Circumstance and Future Prospective
Marawan, M. A., Alouffi, A. S., Eltokhy, S. S., et al. (2021) · Viruses · doi:10.3390/v13112167 · Cited by 89
Role of HTLV-1 Tax and HBZ in the Pathogenesis of HAM/TSP
Enose-Akahata, Y., Vellucci, A., & Jacobson, S. (2017) · Frontiers in Microbiology · doi:10.3389/fmicb.2017.02563 · Cited by 88 · cited 1×
“Treatments for HTLV-1-associated diseases and infection.”
In vivo disassembly of IV administered siRNA matrix nanoparticles at the renal filtration barrier
Naeye, B., Deschout, H. G., Caveliers, V., Descamps, B., Braeckmans, K., Vanhove, C., Demeester, J., Lahoutte, T., Smedt, S. C. D., & Raemdonck, K. (2012) · Biomaterials · doi:10.1016/j.biomaterials.2012.11.058 · Cited by 87
Management of HAM/TSP: Systematic Review and Consensus-based Recommendations 2019
Araujo, A., Bangham, C. R. M., Casseb, J., Gotuzzo, E., Jacobson, S., Martin, F., Penalva de Oliveira, A., Puccioni-Sohler, M., Taylor, G. P., & Yamano, Y. (2021) · Neurology Clinical Practice · doi:10.1212/cpj.0000000000000832 · Cited by 87
Kettmann, R., Marbaix, G., Cleuter, Y., Portetelle, D., Mammerickx, M., & Burny, A. (1980) · Leukemia Research · doi:10.1016/0145-2126(80)90062-4 · Cited by 84
Hukezalie, K. R., Thumati, N. R., Côté, H. C. F., & Wong, J. M. Y. (2012) · PLoS ONE · doi:10.1371/journal.pone.0047505 · Cited by 84
Evidence for the interleukin-2 dependent expansion of leukemic cells in adult T cell leukemia
Maeda, M., Arima, N., Daitoku, Y., Kashihara, M., Okamoto, H., Uchiyama, T., Shirono, K., Matsuoka, M., Hattori, T., & Takatsuki, K. (1987) · Blood · doi:10.1182/blood.v70.5.1407.1407 · Cited by 84 · cited 1×
“Antibody responses against the Gag antigen was only observed in some Balb/c mice, with further studies confirming HTLV-1 persistence but the absence of antibody responses [124].”
BackgroundHuman T-cell leukemia virus type 1 infects multiple lineage hematopoietic cells in vivo
Furuta, R., Yasunaga, J.-I., Miura, M., Sugata, K., Saito, A., Akari, H., Ueno, T., Takenouchi, N., Fujisawa, J.-I., Koh, K.-R., et al. (2017) · PLOS Pathogens · doi:10.1371/journal.ppat.1006722 · Cited by 83
The prevalence and clinical associations of HTLV‐1 infection in a remote Indigenous community
Einsiedel, L. J., Pham, H., Woodman, R. J., Pepperill, C., & Taylor, K. A. (2016) · Medical Journal of Australia · doi:10.5694/mja16.00285 · Cited by 82
Merle, H., Cabre, P., Olindo, S., Merle, S., & Smadja, D. (2002) · American Journal of Ophthalmology · doi:10.1016/s0002-9394(02)01521-0 · Cited by 81 · cited 1×
“HTLV-1-associated arthritis Immunomodulatory therapies such as TNF-α [268] HTLV-1-associated conjunctivitis sicca syndrome and interstitial keratitis Artificial lubricants such as tears, cyclosporine eye drops [264] Relapse is common when treatment is halted.”
BackgroundThe role of EZH1 and EZH2 in development and cancer
Lee, S. H., Li, Y., Kim, H., Eum, S., Park, K., & Lee, C. (2022) · BMB Reports · doi:10.5483/bmbrep.2022.55.12.174 · Cited by 81 · cited 1×
“Treatments for HTLV-1-associated diseases and infection.”
Taylor, G. P., Bod??us, M., Courtois, F., Pauli, G., del Mistro, A., Machuca, A., Padua, E., Andersson, S., Goubau, P., Chieco-Bianchi, L., et al. (2005) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/00126334-200501010-00018 · Cited by 80 · cited 3×
“The The global prevalence of HTLV-1 has been estimated to be anywhere between 3 and 30 million cases [18,19], with estimates based primarily on the serological screening of blood donors, pregnant women, and at-risk population groups [9,20–22]. global prevalence of HTLV-1 has been estimated to be…”
BackgroundLehky, T. J., Levin, M. C., Kubota, R., Bamford, R. N., Flerlage, A. N., Soldan, S. S., Leist, T. P., Xavier, A., White, J. D., Brown, M., et al. (1998) · Annals of Neurology · doi:10.1002/ana.410440613 · Cited by 80 · cited 1×
“…Topical or systemic corticosteroids and mydriatics [263] HTLV-1-associated Sjögren’s Syndrome Artificial lubricants such as saliva/tears replacement solutions coupled with systemic pharmacotherapy with pilocarpine hydrochloride [264] HTLV-1-associated Hashimoto’s thyroiditis and Graves’ disease”
BackgroundMitsuya, H., Matis, L. A., Megson, M., Bunn, P. A., Murray, C., Mann, D. L., Gallo, R. C., & Broder, S. (1983) · The Journal of Experimental Medicine · doi:10.1084/jem.158.3.994 · Cited by 79 · cited 1×
“Other deltaretroviridae include the simian T-lymphotropic virus (STLV-1) and bovine leukaemia virus (BLV), both with large bodies of work useful for modelling HTLV-1 infection.”
BackgroundRetroviral delivery of promoter-targeted shRNA induces long-term silencing of HIV-1 transcription
Yamagishi, M., Ishida, T., Miyake, A., Cooper, D. A., Kelleher, A. D., Suzuki, K., & Watanabe, T. (2009) · Microbes and Infection · doi:10.1016/j.micinf.2009.02.003 · Cited by 77 · cited 1×
“Following previous failed attempts, including DNA vaccines that did not prevent later infection due to transient activation, including recombinant vaccinia virus (RVV) and inactivated BLV, the attenuated BLV succeeded with deletions in genes that regulate infectivity and replication [351].”
MethodSelf-citationDewan, M. Z. (2006) · Blood · doi:10.1182/blood-2005-02-0735 · Cited by 75
Interferon‐β1a therapy in human T‐lymphotropic virus type I–associated neurologic disease
Oh, U., Yamano, Y., Mora, C. A., Ohayon, J., Bagnato, F., Butman, J. A., Dambrosia, J., Leist, T. P., McFarland, H., & Jacobson, S. (2005) · Annals of Neurology · doi:10.1002/ana.20429 · Cited by 74 · cited 1×
“…Topical or systemic corticosteroids and mydriatics [263] HTLV-1-associated Sjögren’s Syndrome Artificial lubricants such as saliva/tears replacement solutions coupled with systemic pharmacotherapy with pilocarpine hydrochloride [264] HTLV-1-associated Hashimoto’s thyroiditis and Graves’ disease”
BackgroundGao, L., Deng, H., Zhao, H., Hirbe, A., Harding, J., Ratner, L., & Weilbaecher, K. (2005) · Blood · doi:10.1182/blood-2005-04-1730 · Cited by 74 · cited 1×
“Overexpression of Hbz was observed to prevent Tax-induced NF-κ B and PRC2 activation, shedding light on the co-modulatory interplay of Tax and Hbz [157].”
BackgroundShimizu, K., Hirano, T., Ishibashi, K., Nakano, N., Taga, T., Sugamura, K., Yamamura, Y., & Kishimoto, T. (1985) · The Journal of Immunology · doi:10.4049/jimmunol.134.3.1728 · Cited by 73 · cited 1×
“The first HTLV-1 carrier mouse model was established in 1997 by intraperitoneal injection of MT-2 into C3H/HeJ and Balb/c strains of immunocompetent neonatal mice [123].”
MethodCurrent concepts regarding the HTLV-1 receptor complex
Ghez, D., Lepelletier, Y., Jones, K. S., Pique, C., & Hermine, O. (2010) · Retrovirology · doi:10.1186/1742-4690-7-99 · Cited by 73 · cited 1×
“The majority of infected cells exist as memory CD4 + T cells, allowing for long-term persistence [76–79], and the subsequent transcriptional silence serves as a potent mechanism evasion of immune system detection.”
BackgroundInfectious transmission of human T‐cell leukemia virus to rabbits
Miyoshi, I., Yoshimoto, S., Kubonishi, I., Fujishita, M., Ohtsuki, Y., Yamashita, M., Yamato, K., Hirose, S., Taguchi, H., Niiya, K., et al. (1985) · International Journal of Cancer · doi:10.1002/ijc.2910350113 · Cited by 72 · cited 1×
“The immediate goal of ART is to reduce the viral load below levels detectable by assays (50 RNA/mL) and to elicit the eventual normalisation of CD4 + T cell count (>500 cells/ µ L) [162,163].”
BackgroundHamlyn, E., Ewings, F. M., Porter, K., Cooper, D. A., Tambussi, G., Schechter, M., Pedersen, C., Okulicz, J. F., McClure, M., Babiker, A., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0043754 · Cited by 71 · cited 2×
“Amino acid sequence alignment of HTLV-1 and HIV-1 RT has shown that the two RTs share ~25% sequence identity and ~45% sequence similarity [73].”
BackgroundMatsuzaki, T., Saito, M., Usuku, K., Nose, H., Izumo, S., Arimura, K., & Osame, M. (2005) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2005.05.011 · Cited by 70 · cited 1×
“…Topical or systemic corticosteroids and mydriatics [263] HTLV-1-associated Sjögren’s Syndrome Artificial lubricants such as saliva/tears replacement solutions coupled with systemic pharmacotherapy with pilocarpine hydrochloride [264] HTLV-1-associated Hashimoto’s thyroiditis and Graves’ disease”
BackgroundMartin, F., Fedina, A., Youshya, S., & Taylor, G. P. (2010) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.2009.191239 · Cited by 70 · cited 14×
“Long-term corticosteroid therapy [265] HTLV-1-associated inflammatory myositis Currently no available therapeutic; myositis is resistant to corticosteroids and immunomodulatory therapies such as cyclosporin [266,267] Table 5.”
BackgroundInfluentialCorticosteroid therapy in TSP/HAM patients: The results from a 10 years open cohort
Croda, M. G., de Oliveira, A. C. P., Vergara, M. P. P., Bonasser, F., Smid, J., Duarte, A. J. D. S., & Casseb, J. (2008) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2008.01.004 · Cited by 70
Phillips, A. A., Fields, P. A., Hermine, O., Ramos, J. C., Beltran, B. E., Pereira, J., Wandroo, F., Feldman, T., Taylor, G. P., Sawas, A., et al. (2019) · Haematologica · doi:10.3324/haematol.2018.205096 · Cited by 70
Vaccination against δ-Retroviruses: The Bovine Leukemia Virus Paradigm
Gutiérrez, G., Rodríguez, S., De Brogniez, A., Gillet, N., Golime, R., Burny, A., Jaworski, J.-P., Alvarez, I., Vagnoni, L., Trono, K., et al. (2014) · Viruses · doi:10.3390/v6062416 · Cited by 69
Early application of related SCT might improve clinical outcome in adult T-cell leukemia/lymphoma
Fuji, S., Fujiwara, H., Nakano, N., Wake, A., Inoue, Y., Fukuda, T., Hidaka, M., Moriuchi, Y., Miyamoto, T., Uike, N., et al. (2015) · Bone Marrow Transplantation · doi:10.1038/bmt.2015.265 · Cited by 69
An animal model of adult T-cell leukemia: humanized mice with HTLV-1–specific immunity
Tezuka, K., Xun, R., Tei, M., Ueno, T., Tanaka, M., Takenouchi, N., & Fujisawa, J.-I. (2014) · Blood · doi:10.1182/blood-2013-06-508861 · Cited by 68 · cited 1×
“Overexpression of Hbz was observed to prevent Tax-induced NF-κ B and PRC2 activation, shedding light on the co-modulatory interplay of Tax and Hbz [157].”
BackgroundA model of in vivo cell proliferation of adult T-cell leukemia
Kondo, A., Imada, K., Hattori, T., Yamabe, H., Tanaka, T., Miyasaka, M., Okuma, M., & Uchiyama, T. (1993) · Blood · doi:10.1182/blood.v82.8.2501.2501 · Cited by 67
Harrington, W. J., Sheremata, W. A., Snodgrass, S. R., Emerson, S., Phillips, S., & Berger, J. R. (1991) · AIDS Research and Human Retroviruses · doi:10.1089/aid.1991.7.1031 · Cited by 67 · cited 1×
“…Topical or systemic corticosteroids and mydriatics [263] HTLV-1-associated Sjögren’s Syndrome Artificial lubricants such as saliva/tears replacement solutions coupled with systemic pharmacotherapy with pilocarpine hydrochloride [264] HTLV-1-associated Hashimoto’s thyroiditis and Graves’ disease”
BackgroundSusceptibility of the Porcine Endogenous Retrovirus to Reverse Transcriptase and Protease Inhibitors
Qari, S. H., Magre, S., Garcia-Lerma, J. G., Hussain, A. I., Takeuchi, Y., Patience, C., Weiss, R. A., & Heneine, W. (2001) · Journal of Virology · doi:10.1128/jvi.75.2.1048-1053.2001 · Cited by 67 · cited 1×
“A caveat, however, is that immunocompetent HTLV-1 carrier mouse models demonstrate very little in vivo spread of infection with no evidence of disease, except for one report of tumorigenesis [125,126].”
BackgroundSabouri, A. H., Saito, M., Lloyd, A. L., Vine, A. M., Witkover, A., Furukawa, Y., Izumo, S., Arimura, K., Marshall, S. E., Usuku, K., et al. (2004) · The Journal of Infectious Diseases · doi:10.1086/423942 · Cited by 67
Cytoplasmic HIV-1 RNA is mainly transported by diffusion in the presence or absence of Gag protein
Chen, J., Grunwald, D., Sardo, L., Galli, A., Plisov, S., Nikolaitchik, O. A., Chen, D., Lockett, S., Larson, D. R., Pathak, V. K., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1413169111 · Cited by 66 · cited 1×
“Transcriptional activity is regulated at the epigenetic level through changes in the 5 ′ viral promoter in the LTR, namely via DNA methylation or at the genetic level by deletion.”
BackgroundHTLV-1 Propels Thymic Human T Cell Development in “Human Immune System” Rag2-/- gamma c-/- Mice
Villaudy, J., Wencker, M., Gadot, N., Gillet, N. A., Scoazec, J.-Y., Gazzolo, L., Manz, M. G., Bangham, C. R. M., & Dodon, M. D. (2011) · PLoS Pathogens · doi:10.1371/journal.ppat.1002231 · Cited by 66 · cited 1×
“Overexpression of Hbz was observed to prevent Tax-induced NF-κ B and PRC2 activation, shedding light on the co-modulatory interplay of Tax and Hbz [157].”
BackgroundMacchi, B., Grelli, S., Favalli, C., Mastino, A., Bonmassar, E., Faraoni, I., & Zhang, J. (1997) · Journal of General Virology · doi:10.1099/0022-1317-78-5-1007 · Cited by 66 · cited 1×
“This will be discussed further in Section 2.2.”
BackgroundInfluentialAhsan, M. K., Masutani, H., Yamaguchi, Y., KIM, Y. C., Nosaka, K., Matsuoka, M., Nishinaka, Y., Maeda, M., & Yodoi, J. (2005) · Oncogene · doi:10.1038/sj.onc.1209256 · Cited by 65 · cited 1×
“Antibody responses against the Gag antigen was only observed in some Balb/c mice, with further studies confirming HTLV-1 persistence but the absence of antibody responses [124].”
BackgroundHTLV‐I infection in patients with autoimmune thyroiditis (Hashimoto's thyroiditis)
Kawai, H., Inui, T., Kashiwagi, S., Tsuchihashi, T., Masuda, K., Kondo, A., Niki, S., Iwasa, M., & Saito, S. (1992) · Journal of Medical Virology · doi:10.1002/jmv.1890380212 · Cited by 65 · cited 1×
“Cont.”
HTLV-1 Extracellular Vesicles Promote Cell-to-Cell Contact
Pinto, D. O., DeMarino, C., Pleet, M. L., Cowen, M., Branscome, H., Al Sharif, S., Jones, J., Dutartre, H., Lepene, B., Liotta, L. A., et al. (2019) · Frontiers in Microbiology · doi:10.3389/fmicb.2019.02147 · Cited by 64
Colven, R., Harrington, R. D., Spach, D. H., Cohen, C. J., & Hooton, T. M. (2000) · Annals of Internal Medicine · doi:10.7326/0003-4819-133-6-200009190-00010 · Cited by 63 · cited 1×
“Amino acid sequence alignment of HTLV-1 and HIV-1 RT has shown that the two RTs share ~25% sequence identity and ~45% sequence similarity [73].”
BackgroundKazanji, M., Tartaglia, J., Franchini, G., de Thoisy, B., Talarmin, A., Contamin, H., Gessain, A., & de Thé, G. (2001) · Journal of Virology · doi:10.1128/jvi.75.13.5939-5948.2001 · Cited by 63 · cited 1×
“This section discusses current interventions, with a focus on the limitations of ART in the treatment of HTLV-1 and its associated diseases.”
BackgroundPromoter Targeting shRNA Suppresses HIV-1 Infection In vivo Through Transcriptional Gene Silencing
Suzuki, K., Hattori, S., Marks, K., Ahlenstiel, C., Maeda, Y., Ishida, T., Millington, M., Boyd, M., Symonds, G., Cooper, D. A., et al. (2013) · Molecular Therapy - Nucleic Acids · doi:10.1038/mtna.2013.64 · Cited by 61 · cited 2×
“Such a vaccine for HTLV-1 could be distributed to at-risk populations in endemic regions.”
BackgroundMethodSelf-citationNovel RNA Duplex Locks HIV-1 in a Latent State via Chromatin-mediated Transcriptional Silencing
Ahlenstiel, C., Mendez, C., Lim, S. T. H., Marks, K., Turville, S., Cooper, D. A., Kelleher, A. D., & Suzuki, K. (2015) · Molecular Therapy - Nucleic Acids · doi:10.1038/mtna.2015.31 · Cited by 60 · cited 1×
“Such a vaccine for HTLV-1 could be distributed to at-risk populations in endemic regions.”
BackgroundSelf-citationImada, K., Takaori-Kondo, A., Akagi, T., Shimotohno, K., Sugamura, K., Hattori, T., Yamabe, H., Okuma, M., & Uchiyama, T. (1995) · Blood · doi:10.1182/blood.v86.6.2350.bloodjournal8662350 · Cited by 60 · cited 1×
“NHPs indeed recapitulate most aspects of viral infection, replication, and pathogenesis; however, the high cost of research and regulations underpin its scarce use in experimental research.”
BackgroundIhrke, P. J., Norton, A. L., Ling, G. V., & Stannard, A. A. (1985) · Journal of the American Veterinary Medical Association · doi:10.2460/javma.1985.186.01.43 · Cited by 60 · cited 1×
“…Topical or systemic corticosteroids and mydriatics [263] HTLV-1-associated Sjögren’s Syndrome Artificial lubricants such as saliva/tears replacement solutions coupled with systemic pharmacotherapy with pilocarpine hydrochloride [264] HTLV-1-associated Hashimoto’s thyroiditis and Graves’ disease”
Background
Research works printed but not linked: 2
- Ribas, 2002, Infection and disease caused by the human T cell lymphotropic viruses type I and II in Brazil, Rev. Soc. Bras. Med. Trop., 35, 499
- Cruz, 2012, Chronic rhinitis in HTLV-1 carriers: A histopathologic study, Braz. J. Otorhinolaryngol., 78, 35
Cited by
Viral oncogenesis in cancer: from mechanisms to therapeutics
Xiao, Q., Liu, Y., Li, T., Wang, C., He, S., Zhai, L., Yang, Z., Zhang, X., Wu, Y., & Liu, Y. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02197-9 · Cited by 128
Human T-Lymphotropic Virus (HTLV): Epidemiology, Genetic, Pathogenesis, and Future Challenges
Branda, F., Romano, C., Pavia, G., Bilotta, V., Locci, C., Azzena, I., Deplano, I., Pascale, N., Perra, M. T., Giovanetti, M., et al. (2025) · Viruses · doi:10.3390/v17050664 · Cited by 47
“Currently, treatment options for HTLV-1 are limited and focus primarily on symptom management, with few curative interventions available [171].”
Combination antiretroviral therapy and MCL-1 inhibition mitigate HTLV-1 infection in vivo
Cooney, J. P., Hirons, A., Jansz, N., Allison, C. C., Hickey, P. F., Teh, C. E., Tan, T., Dagley, L. F., Yousef, J. M., Yurick, D., et al. (2025) · Cell · doi:10.1016/j.cell.2025.06.023 · Cited by 18
Self-citationOncoviruses in the Oral Cavity: Recent Advances in Understanding Viral Infections and Tumorigenesis
Campos, L., Guimarães, A. C. S., Pereira, J. G., da Silva, C. S., de Almeida, N. A. A., Marinho, P. D. N., de Sousa, R. M. P., Duś‐Ilnicka, I., & de Paula, V. S. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26146721 · Cited by 10
“Therefore, this vaccine may provide a model against HTLV-1 that requires the stimulation of humoral and cytotoxic immune responses [274,278].”
Mikame, Y., Toyama, H., Dohno, C., Wada, T., & Yamayoshi, A. (2025) · Communications Chemistry · doi:10.1038/s42004-025-01416-2 · Cited by 5
Metadata
- Authors
- Wang, T. T., Hirons, A., Doerflinger, M., Morris, K. V., Ledger, S., Purcell, D. F. J., Kelleher, A. D., & Ahlenstiel, C. L.
- Affiliations
- UNSW Sydney (AU)
- The University of Melbourne (AU)
- Queensland University of Technology (AU)
- Corresponding author
- Ahlenstiel, Chantelle L.
- ORCID
- Venue
- Viruses
- Publisher
- MDPI AG
- Published
- 2024-10-15
- Volume
- 16
- Issue
- 10
- Pages
- 1616
- ISSN
- 1999-4915 (ISSN-L)
- PMC
- PMC11512412
- OpenAlex
- W4403429851
- Cited by
- 22
- References
- 372
- Citations by year
- 2026: 9 · 2025: 12 · 2024: 1
- FWCI
- 0.97
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Viruses (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Minerva Access (University of Melbourne) (submittedVersion, cc-by)
- Funders
- an Australian Government Research Training Program Scholarship (APP1149990, GNT2004670, R01 1R01MH134389-01 NIMH)
- an NHMRC programme grant (APP1149990, GNT2004670, R01 1R01MH134389-01 NIMH)
- a UNSW Rapid Response Research grant (APP1149990, GNT2004670, R01 1R01MH134389-01 NIMH)
- the NSW RNA Production Research Network (APP1149990, GNT2004670, R01 1R01MH134389-01 NIMH)
- a philanthropic grant to the Immunotherapy Research Fund at the Kirby Institute (APP1149990, GNT2004670, R01 1R01MH134389-01 NIMH)
- the Australian NHMRC Ideas grant (APP1149990, GNT2004670, R01 1R01MH134389-01 NIMH)
- Australian Centre for HIV and Hepatitis Virology Research (ACH4) Project Grants (APP1149990, GNT2004670, R01 1R01MH134389-01 NIMH)
- the ACH4 and the Phyllis Connor Memorial Trust (APP1149990, GNT2004670, R01 1R01MH134389-01 NIMH)
- NIH (APP1149990, GNT2004670, R01 1R01MH134389-01 NIMH)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and Retrovirus Studies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Life Sciences › Immunology and Microbiology › Virology › HIV Research and Treatment
- Keywords
- HTLV-1, antiviral agents, gene therapy, adult T-cell leukemia/lymphoma, tropical spastic paraparesis, retroviral infection, CD4+ T cells, HIV-1, vaccine development, animal models, oncogenic retroviruses
- MeSH terms
- Animals, Antiviral Agents, Humans, Viral Vaccines, Human T-lymphotropic virus 1, Leukemia-Lymphoma, Adult T-Cell, HTLV-I Infections
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol and qwen3.8-omni-flash).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.